BioVeris completes merger with Roche.

BioVeris Corporation's (Gaithersburg, MD) stockholders voted to approve Roche's (Basel, Switzerland) acquisition of BioVeris.

The acquisition will allow Roche Diagnostics to expand its immunochemistry business from the human diagnostic field into new market segments such as

life science research, life science development, patient self testing, veterinary testing, drug discovery, drug development and clinical trials. By acquiring BioVeris, Roche will own the complete patent estate of the electrochemiluminescence (ECL) technology deployed in its Elecsys product line which gives Roche Diagnostics the opportunity to fully exploit the entire immunochemistry market.

Samuel J. Wohlstadter, former Chairman and Chief Executive Officer of BioVeris, said: "I am extremely pleased that this transaction was successfully completed. I want to thank all of BioVeris' customers, stockholders and employees for their support throughout this process."

In connection with the transaction, two newly formed entities established by Mr. Wohlstadter purchased from BioVeris rights to certain intellectual property and related assets associated with BioVeris's vaccines research and a non-exclusive limited license to use the ECL technology. These transactions with Mr. Wohlstadter were approved by a Special Committee of independent directors of BioVeris's board.

BioVeris is a global health care and biosecurity company developing proprietary technologies in diagnostics and vaccinology. The company is dedicated to the development and commercialization of innovative products and services for healthcare providers, their patients and their communities.

Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the global leader in biotechnology, Roche contributes on a broad range of fronts to improving people's health and quality of life by supplying innovative products and services for the early detection, prevention, diagnosis and treatment of diseases. Roche is the world leader in in-vitro diagnostics, the leading supplier of drugs for cancer and transplantation and a market leader in virology. It is also engaged in other important therapeutic areas including autoimmune, inflammatory and metabolic disease and diseases of the central nervous system. In 2006 sales by the Pharmaceuticals Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 people worldwide and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai.

BioVeris Corporation

+1-301-869-9800

www.bioveris.com

Roche

www.roche.com